登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of Combination Therapy in Patients With Resectable Liver Cancer
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由广东医科大学附属医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07684040,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
4. CNLC stage Ib, IIa, IIb, or IIIa HCC (excluding patients with main portal vein tumor thrombus).
入选标准第 4 条
7. Child-Pugh class A liver function.
入选标准第 7 条
6. No prior systemic treatment for HCC, including chemotherapy, targeted therapy, or immunotherapy.
入选标准第 6 条
10. For patients with active HBV infection, effective antiviral therapy is required, with HBV DNA ≤2000 IU/mL or a ≥10-fold reduction after antiviral treatment.
入选标准第 14 条
3. Planned or prior organ transplantation or allogeneic bone marrow transplantation.
排除标准第 3 条
8. ECOG performance status 0-1.
入选标准第 8 条
ANC ≥1.5 × 10\^9/L; Platelet count ≥75 × 10\^9/L; Hemoglobin ≥90 g/L.
入选标准第 10 条
Albumin ≥30 g/L; Total bilirubin ≤1.5 × ULN; ALT, AST, and ALP ≤5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance >50 mL/min.
入选标准第 11 条
1. Intrahepatic cholangiocarcinoma, sarcomatoid HCC, mixed hepatocellular carcinoma, fibrolamellar carcinoma, or any other active malignancy within the past 5 years (except HCC).
排除标准第 1 条
11. Women of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during the study and for 6 months after study completion. Male participants must also use effective contraception during the study and for 6 months after study completion.
入选标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07684040,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
1. Voluntarily signed written informed consent. 2. Age ≥18 years; male or female. 3. Histologically, cytologically, or clinically confirmed hepatocellular carcinoma (HCC) according to EASL/AASLD criteria. 4. CNLC stage Ib, IIa, IIb, or IIIa HCC (excluding patients with main portal vein tumor thrombus). 5. Presence of vascular invasion and no extrahepatic metastasis, including PVTT (Vp1-Vp3), HVTT, or IVCTT. 6. No prior systemic treatment for HCC, including chemotherapy, targeted therapy, or immunotherapy. 7. Child-Pugh class A liver function. 8. ECOG performance status 0-1. 9. Adequate organ function: ANC ≥1.5 × 10\^9/L; Platelet count ≥75 × 10\^9/L; Hemoglobin ≥90 g/L. Albumin ≥30 g/L; Total bilirubin ≤1.5 × ULN; ALT, AST, and ALP ≤5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance >50 mL/min. INR ≤2.3 or PT prolongation ≤6 seconds. Urine protein <2+; if ≥2+, 24-hour urine protein <1.0 g. 10. For patients with active HBV infection, effective antiviral therapy is required, with HBV DNA ≤2000 IU/mL or a ≥10-fold reduction after antiviral treatment. 11. Women of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during the study and for 6 months after study completion. Male participants must also use effective contraception during the study and for 6 months after study completion.排除标准:Exclusion Criteria:
1. Intrahepatic cholangiocarcinoma, sarcomatoid HCC, mixed hepatocellular carcinoma, fibrolamellar carcinoma, or any other active malignancy within the past 5 years (except HCC). 2. Severe allergy to iodinated contrast agents that prevents HAIC treatment. 3. Planned or prior organ transplantation or allogeneic bone marrow transplantation. 4. Treatment with another investigational drug within 28 days before study treatment. 5. Current or prior central nervous system metastases. 6. History of hepatic encephalopathy. 7. Current interstitial pneumonitis or interstitial lung disease. 8. Active autoimmune disease or history of autoimmune disease with risk of recurrence. 9. Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes within 14 days before study treatment. 10. Severe infection within 4 weeks before study treatment. 11. Gastrointestinal bleeding within 6 months before study treatment or a known risk of gastrointestinal bleeding. 12. Known hereditary or acquired bleeding disorders or thrombotic tendency. 13. Uncontrolled clinically significant cardiac disease or symptoms. 14. Moderate or severe ascites requiring therapeutic drainage or paracentesis. 15. Major vascular disease within 6 months before study treatment. 16. Inability to swallow oral medication, malabsorption syndrome, or any condition affecting gastrointestinal absorption. 17. Known hypersensitivity to any study drug, its excipients, monoclonal antibodies, or anti-angiogenic agents. 18. Any other serious acute or chronic medical condition, psychiatric disorder, or laboratory abnormality that may increase study risk, interfere with study results, or make the patient unsuitable for participation.
引自 ClinicalTrials.gov, NCT07684040, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07684040,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。